Merrimack Pharmaceuticals, Inc.
$15.14▲ 0.10%(+$0.01)
TickerSpark Score
65/100
▌ Solid
55
Valuation
30
Profitability
55
Growth
84
Health
100
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MACK research report →
52-Week Range83% of range
Low
$11.53
Current
$15.14
High
$15.89
Company Overviewwww.merrimack.com
About the company
Founded in 1993, Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts.
- CEO
- Gary L. Crocker
- IPO
- 2012
- HQ
- Cambridge, MA, US
Price Chart
+21.04% · this period
Valuation
- Market Cap
- $223.97M
- P/E
- -183.35
- P/S
- 0.00
- P/B
- 11.55
- EV/EBITDA
- 216.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -6.22%
- ROIC
- -11.61%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,181,000 · 23.51%
- EPS
- $-0.08 · 24.91%
- Op Income
- $-2,176,000
- FCF YoY
- 12.63%
Performance & Tape
- 52W High
- $15.89
- 52W Low
- $11.53
- 50D MA
- $14.80
- 200D MA
- $13.36
- Beta
- 1.42
- Avg Volume
- 182.63K
Get TickerSpark's AI analysis on MACK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Form 4 · Filings
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 28, 23 | Andersen Eric | buy | 857 |
| Dec 26, 23 | Andersen Eric | buy | 48,693 |
| Dec 7, 23 | Andersen Eric | buy | 76,384 |
| Dec 7, 23 | Andersen Eric | buy | 24,666 |
| Nov 17, 23 | Andersen Eric | buy | 235 |
| Nov 17, 23 | Andersen Eric | buy | 65 |
| Nov 14, 23 | Andersen Eric | buy | 39,283 |
| Nov 14, 23 | Andersen Eric | buy | 10,887 |
| Nov 9, 23 | Andersen Eric | buy | 7,810 |
| Nov 8, 23 | Andersen Eric | buy | 4,783 |
Coverage · MACK
Our MACK coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on MACK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MACK report →Internal Compare
Similar companies
Peers in the same neighborhood.
SLRN▲0.00%
Acelyrin, Inc.
$2.27
CRGX▲0.00%
CARGO Therapeutics, Inc. Common Stock
$4.47
SPPI▼0.49%
Spectrum Pharmaceuticals, Inc.
$1.02
THRD▼0.09%
Third Harmonic Bio, Inc.
$5.38
TCRT▼3.70%
Alaunos Therapeutics, Inc.
$2.08
INXB▲13.94%
Inhibrx Biosciences, Inc.
$15.86
CBLI▼7.31%
Cytocom, Inc.
$3.17
ZVRA▲1.23%
Zevra Therapeutics, Inc.
$13.98